Clinical Trial Update: A Phase 3B, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy [Phase 3]

View source ↗

Summary

Phase 3B open-label study assessing efficacy and safety of apremilast in plaque psoriasis not adequately controlled by topical therapy; completed with results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Apremilast (apremilast)

Snippet

Sponsor: Amgen | Conditions: Plaque Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2022-01-20